Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Thomas F. Rocereto"'
Autor:
Thomas J. Herzog, Katherine Y. Look, Michael A. Bookman, Jennifer Vinters, Jessie Schol, Thomas F. Rocereto
Publikováno v:
Gynecologic Oncology. 92:93-100
Purpose . To determine the feasibility of administering a minimum of four cycles of carboplatin, paclitaxel, and gemcitabine (CPG) every 21 days without excessive dose modification or cycle delay in patients with previously untreated epithelial ovari
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7403ac8756c951b2eaaa98b921de669a
https://doi.org/10.1016/j.ygyno.2003.09.019
https://doi.org/10.1016/j.ygyno.2003.09.019
Autor:
Thomas F. Rocereto, Steven E Waggoner, John A. Blessing, Jonathan S. Berek, Judith K. Wolf, Paula M. Fracasso
Publikováno v:
Gynecologic Oncology. 90:177-180
Objective A phase II study was conducted to determine the efficacy of oxaliplatin therapy in patients with previously treated squamous cell carcinoma of the cervix. Methods Eligible patients were to have measurable disease and not more than one prior
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1f5999d058d215c5a6ea2ba59afeeb6
https://doi.org/10.1016/s0090-8258(03)00253-1
https://doi.org/10.1016/s0090-8258(03)00253-1
Publikováno v:
Gynecologic Oncology. 88:277-281
Objective To estimate the antitumor activity of paclitaxel (Taxol) in patients with persistent or recurrent endometrial carcinoma who have failed prior chemotherapy. To determine the nature and degree of toxicity of paclitaxel in this group of patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13fe3dcdec3b6712a174fa2c67a26592
https://doi.org/10.1016/s0090-8258(02)00068-9
https://doi.org/10.1016/s0090-8258(02)00068-9
Autor:
Laurie Small, Robert S. Mannel, Thomas F. Rocereto, William E. Brady, Mark S. Shahin, James S. Hoffman, Jacob Rotmensch
Publikováno v:
Gynecologic oncology. 116(3)
Objective To evaluate the effectiveness and toxicity of mifepristone in patients with ovarian, peritoneal and fallopian tube cancers. Methods Patients with confirmed epithelial ovarian, peritoneal and fallopian tube cancers which were persistent or r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34263bb3e540756b47439f43231c4c6b
https://pubmed.ncbi.nlm.nih.gov/19922989
https://pubmed.ncbi.nlm.nih.gov/19922989
Autor:
Robert S. Mannel, Olga B. Ioffe, Thomas F. Rocereto, Aaron H. Wolfson, Yi-Chun Lee, David E. Cohn, Robert J. Futoran, Mark F. Brady
Purpose After initial surgery, there has been no established consensus regarding adjunctive therapy for patients with uterine carcinosarcoma (CS). This study was designed to compare patient outcome following treatment with adjuvant whole abdominal ir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24ea387c2c676a7b3c197cd2552bdfab
https://europepmc.org/articles/PMC2752331/
https://europepmc.org/articles/PMC2752331/
Autor:
Jo Ann Benda, George J. Olt, David H. Moore, David Miller, Howard T. Thaler, Stephanie King, John A. Blessing, David Cella, Thomas F. Rocereto, Richard P. McQuellon, John F. Boggess
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 22(15)
Purpose To determine whether cisplatin plus paclitaxel (C+P) improved response rate, progression-free survival (PFS), or survival compared with cisplatin alone in patients with stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::975ed7e8b9897bdcd37bbb130dd7983c
https://pubmed.ncbi.nlm.nih.gov/15611523
https://pubmed.ncbi.nlm.nih.gov/15611523
Autor:
Jeffrey D. Bloss, Edward E. Partridge, Shu Yuan Liao, Daniel L. Clarke-Pearson, Mark F. Brady, Thomas F. Rocereto
Publikováno v:
Gynecologic oncology. 89(1)
Objectives The goals of this study were first, to assess the clinical effectiveness of cisplatin and cyclophosphamide in a phase II study involving a well-defined group of women with extraovarian peritoneal serous papillary carcinoma (EPSPC); and sec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01034fc228d0e8b2d932ac34b4922f03
https://pubmed.ncbi.nlm.nih.gov/12694669
https://pubmed.ncbi.nlm.nih.gov/12694669
Publikováno v:
American journal of clinical oncology. 25(6)
This Gynecologic Oncology Group (GOG) study was designed to estimate the activity of goserelin acetate as treatment for advanced and recurrent endometrial carcinoma. Forty evaluable patients received monthly treatment with goserelin acetate at a dose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85cae54bc2275e70c30fc62b162324fd
https://pubmed.ncbi.nlm.nih.gov/12477997
https://pubmed.ncbi.nlm.nih.gov/12477997
Publikováno v:
Gynecologic oncology. 77(3)
Objective. A phase II study of Mifepristone (RU486) was conducted in patients with ovarian cancer whose tumors were resistant to cisplatin and paclitaxel, alone or in combination. Patients and Methods. Forty-four patients were accrued into this study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70a65d7c85a9bd0080a66cbd35f14ef0
https://pubmed.ncbi.nlm.nih.gov/10831354
https://pubmed.ncbi.nlm.nih.gov/10831354
Autor:
Mark S. Shahin, William E. Brady, Thomas F. Rocereto, Laurie Small, Robert S. Mannel, Jacob Rotmensch, James S. Hoffman
Publikováno v:
Gynecologic Oncology. 118:208
a Cooper University Hospital, Camden, NJ 08103, USA b Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY 14263, USA c Abington Memorial Hospital, Abington, PA 19001, USA d The Hospital of Central Connec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b9f90aadd471fedd5dfd61af45aac6ec
https://doi.org/10.1016/j.ygyno.2010.04.019
https://doi.org/10.1016/j.ygyno.2010.04.019